| Primary | Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 1-3 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 1-3 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 4-6 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 4-6 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 7-9 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 7-9 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 10-12 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 10-12 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 13-15 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 13-15 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 16-18 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 16-18 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 19-21 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 19-21 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) After 21 Months up to 36 Months | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | After 21 Months up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (100 to 130 g/L) at Baseline | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Baseline | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 1-3 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 1-3 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 4-6 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 4-6 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 7-9 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 7-9 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 10-12 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 10-12 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 13-15 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 13-15 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 16-18 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 16-18 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 19-21 | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | At Months 19-21 | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Primary | Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) After 21 Months up to 36 Months | If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation. | Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame. | Posted | | Number | | Percentage of participants | | After 21 Months up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Secondary | Median Time in Which Hb Value Was Maintained Within Target Range of 110-120 g/L | | Analysis population included all enrolled participants. | Posted | | Median | Full Range | Months | | Up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| | |
| Secondary | Median Time in Which Hb Value Was Maintained Within Target Range of 100-130 g/L | | Analysis population included all enrolled participants. | Posted | | Median | Full Range | Months | | Up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| | |
| Secondary | Average Dose of Methoxy Polyethylene Glycol-Epoetin Beta | Average dose of methoxy polyethylene glycol-epoetin beta administered at Baseline | Analysis population included all enrolled participants. | Posted | | Mean | Standard Deviation | microgram | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Secondary | Median Dose of Methoxy Polyethylene Glycol-Epoetin Beta | Median monthly dose of methoxy polyethylene glycol-epoetin beta administered in the study up to 36 months. | Analysis population included all enrolled participants. Here, n signifies participants with available data at specified time-point. | Posted | | Median | Full Range | microgram | | Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and After 21 Months up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Secondary | Number of Dose Adaptations | Total number of changes (increase or decrease) in daily methoxy polyethylene glycol-epoetin beta doses. The reasons for dose-adaptations included: inflammation or infection; kidney function decline; over-response; iron deficiency; insufficient response; adverse effect; start of maintenance dose; kidney function improvement; re-introduction of treatment; and others (other reasons than specified). | Analysis population included all enrolled participants. | Posted | | Number | | Events | | Up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Secondary | Percentage of Participants With Dose 0 | Percentage of participants who did not use methoxy polyethylene glycol-epoetin beta (Dose 0) at atleast one visit during study period. | Analysis population included all enrolled participants. | Posted | | Number | | Percentage of participants | | Up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |
| Secondary | Percentage of Participants With Iron Replacement | Iron replacement was given to the participants either in oral iron replacement or intravenous replacement or both. | Analysis population included all enrolled participants. | Posted | | Number | | Percentage of participants | | Up to 36 Months | | | | ID | Title | Description |
|---|
| OG000 | Methoxy Polyethylene Glycol-Epoetin Beta | Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months. |
| |